Literature DB >> 15353918

Factor V G1691A, prothrombin G20210A, and methylenetetrahydrofolate reductase [MTHFR] C677T gene polymorphism in angiographically documented coronary artery disease.

Wassim Y Almawi1, Ghada Ameen, Hala Tamim, Ramzi R Finan, Noha Irani-Hakime.   

Abstract

BACKGROUND: Single point mutations in the genes coding for factor V [G1691A; Leiden], prothrombin [PRT; G20210A], and methylenetetrahydrofolate reductase [MTHFR, C677T] were shown to be major inherited predisposing factors for venous thromboembolism. However, their contribution in the development of coronary artery disease [CAD] remains controversial. The aim of the study was to examine the association of these mutations in CAD.
METHODS: A total of 96 patients with angiographically-demonstrated CAD [mean age 55.3 +/- 11.3], and 404 healthy subjects [mean age 50.7 +/- 8.9] were recruited into the study. Fasting plasma homocysteine was determined by HPLC, and genotype analysis was assessed by PCR-RFLP.
RESULTS: The carrier frequency of factor V-Leiden (14.6% vs. 15.1%, p = 0.617) and PRT G20210A (3.1% vs. 3.0%; p = 0.936) were similar between patients and controls, respectively. In contrast, the frequency of the MTHFR variant C677T was 71.9% among patients compared with 45.5% in controls (p < 0.001), of which the T/T genotype was significantly higher among patients (31.3%) than controls (4.5%; p < 0.001). Significantly higher homocysteine levels were seen among T/T genotype in both groups compared to non-T/T carriers (p < 0.05), and among patients compared with controls (18.47 +/- 3.73 micromol/L vs. 16.28 +/- 4.16 micromol/L). In addition, the coexistence of MTHFR C677T with FV-Leiden was seen in 10.4% of CAD patients compared 6.9% of controls (p = 0.001).
CONCLUSION: While results from this study clearly demonstrate a strong association of hyperhomocysteinemia and homozygosity of the MTHFR C677T, but not FV-Leiden or PRT G20210A, mutations with confirmed CAD, they also suggest a potential role for factor V-Leiden in MTHFR C677T carriers.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15353918     DOI: 10.1023/B:THRO.0000040489.86029.27

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  41 in total

1.  Cleavage of factor V at Arg 506 by activated protein C and the expression of anticoagulant activity of factor V.

Authors:  E Thorelli; R J Kaufman; B Dahlbäck
Journal:  Blood       Date:  1999-04-15       Impact factor: 22.113

2.  High prevalence of Factor V Leiden mutation among healthy individuals and patients with deep venous thrombosis in Lebanon: is the eastern Mediterranean region the area of origin of this mutation?

Authors:  A Taher; I Khalil; A Shamseddine; F El-Ahdab; A Bazarbachi
Journal:  Thromb Haemost       Date:  2001-08       Impact factor: 5.249

3.  Prevalence of the 20210 G-->A prothrombin variant and its association with coronary artery disease in a Middle Eastern Arab population.

Authors:  Khaled K Abu-Amero; Carol A Wyngaard; Marios Kambouris; Nduna Dzimiri
Journal:  Arch Pathol Lab Med       Date:  2002-09       Impact factor: 5.534

4.  Factor V R506Q mutation-Leiden: an independent risk factor for venous thrombosis but not coronary artery disease.

Authors:  N Irani-Hakime; H Tamim; G Elias; S Choueiry; R Kreidy; J L Daccache; W Y Almawi
Journal:  J Thromb Thrombolysis       Date:  2001-04       Impact factor: 2.300

5.  Increased prevalence of the G20210A prothrombin gene variant in acute coronary syndromes without metabolic or acquired risk factors or with limited extent of disease.

Authors:  F Burzotta; K Paciaroni; V De Stefano; P Chiusolo; A Manzoli; I Casorelli; A M Leone; E Rossi; G Leone; A Maseri; F Andreotti
Journal:  Eur Heart J       Date:  2002-01       Impact factor: 29.983

6.  Major and potential prothrombotic genotypes in a cohort of patients with venous thromboembolism.

Authors:  M L Varela; Y P Adamczuk; R R Forastiero; M E Martinuzzo; G S Cerrato; G Pombo; L O Carreras
Journal:  Thromb Res       Date:  2001-12-01       Impact factor: 3.944

7.  Plasma homocysteine, methylenetetrahydrofolate reductase genotypes, and age at onset of symptoms of myocardial ischemia.

Authors:  Aviv Mager; Alexander Battler; Yochai Birnbaum; Nurit Magal; Mordechai Shohat
Journal:  Am J Cardiol       Date:  2002-04-15       Impact factor: 2.778

8.  Hyperhomocyst(e)inemia is a risk factor for arterial endothelial dysfunction in humans.

Authors:  K S Woo; P Chook; Y I Lolin; A S Cheung; L T Chan; Y Y Sun; J E Sanderson; C Metreweli; D S Celermajer
Journal:  Circulation       Date:  1997-10-21       Impact factor: 29.690

9.  Prothrombotic coagulation defects and cardiovascular risk factors in young women with acute myocardial infarction.

Authors:  Bea C Tanis; Daisy G M Bloemenkamp; Maurice A A J van den Bosch; Jeanet M Kemmeren; Ale Algra; Yolanda van de Graaf; Frits R Rosendaal
Journal:  Br J Haematol       Date:  2003-08       Impact factor: 6.998

10.  The common mutations C677T and A1298C in the human methylenetetrahydrofolate reductase gene are associated with hyperhomocysteinemia and cardiovascular disease in hemodialysis patients.

Authors:  Y S Haviv; V Shpichinetsky; N Goldschmidt; I Abou Atta; A Ben-Yehuda; G Friedman
Journal:  Nephron       Date:  2002-09       Impact factor: 2.847

View more
  13 in total

1.  Varied association of prothrombin G20210A polymorphism with coronary artery disease susceptibility in different ethnic groups: evidence from 15,041 cases and 21,507 controls.

Authors:  Bo Jin; Yong Li; Qu-Zhen Ge-Shang; Huan-Chun Ni; Hai-Ming Shi; Wei Shen
Journal:  Mol Biol Rep       Date:  2010-11-16       Impact factor: 2.316

2.  A case control study on the contribution of factor V-Leiden, prothrombin G20210A, and MTHFR C677T mutations to the genetic susceptibility of deep venous thrombosis.

Authors:  Wassim Y Almawi; Hala Tamim; Raghid Kreidy; Georgina Timson; Elias Rahal; Malak Nabulsi; Ramzi R Finan; Noha Irani-Hakime
Journal:  J Thromb Thrombolysis       Date:  2005-06       Impact factor: 2.300

3.  Multiple thrombophilia mutations as a possible cause of premature myocardial infarction.

Authors:  Gabriela Dostálová; Jan Bělohlávek; Zuzana Hlubocká; Kristýna Bayerová; Petra Bobčiková; Tomáš Kvasnička; Jan Kvasnička; Aleš Linhart; Debora Karetová
Journal:  Wien Klin Wochenschr       Date:  2017-04-05       Impact factor: 1.704

4.  Association of MTHFR genetic polymorphisms with venous thromboembolism in Uyghur population in Xinjiang, China.

Authors:  Zhao Li; Umesh Yadav; Ailiman Mahemuti; Bao-Peng Tang; Halmurat Upur
Journal:  Int J Clin Exp Med       Date:  2015-10-15

5.  Distribution of MTHFR C677T Gene Polymorphism in Healthy North Indian Population and an Updated Meta-analysis.

Authors:  Upendra Yadav; Pradeep Kumar; Sanjay Gupta; Vandana Rai
Journal:  Indian J Clin Biochem       Date:  2016-10-11

6.  Impact of hemostatic gene single point mutations in patients with non-diabetic coronary artery disease.

Authors:  Ahmet Var; Ozan Utük; Sinem Akçali; Tamer Sanlidağ; Bekir S Uyanik; Gönül Dinç
Journal:  Mol Biol Rep       Date:  2009-01-03       Impact factor: 2.316

7.  Methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism and high plasma homocysteine in chronic hepatitis C (CHC) infected patients from the Northeast of Brazil.

Authors:  Erika R F Siqueira; Cláudia P M S Oliveira; Maria T C Muniz; Filipe Silva; Leila M M B Pereira; Flair J Carrilho
Journal:  Nutr J       Date:  2011-08-19       Impact factor: 3.271

8.  Thrombotic genetic risk factors and warfarin pharmacogenetic variants in São Miguel's healthy population (Azores).

Authors:  Claudia C Branco; Tânia Pereirinha; Rita Cabral; Paula R Pacheco; Luisa Mota-Vieira
Journal:  Thromb J       Date:  2009-06-18

9.  Impact of Genetic Polymorphism of methylenetetrahydrofolate reductase C677T on Development of Hyperhomocysteinemia and Related Oxidative Changes in Egyptian β-Thalassemia Major Patients.

Authors:  Mai A Abd-Elmawla; Sherine M Rizk; Ilham Youssry; Amira A Shaheen
Journal:  PLoS One       Date:  2016-05-17       Impact factor: 3.240

10.  Does the MTHFR C677T gene polymorphism indicate cardiovascular disease risk in type 2 diabetes mellitus patients?

Authors:  Anzel Bahadır; Recep Eroz; Yasin Türker
Journal:  Anatol J Cardiol       Date:  2014-05-02       Impact factor: 1.596

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.